Table 3

Number of patients in subgroup analysis, adherence to therapy, and hazard ratios for stopping treatment

Patients included February through December 1999

Patients included February 2000 through June 2001

Adherence to therapy after 1 year (2 years)

Hazard ratio (95% CI)

Hazard ratio (95% CI), time-dependent Cox regression analysis

Etanercept and MTX

58

5^a

90% (87%)

3.27 (1.76; 6.08)

3.15 (1.84; 5.39)

Infliximab and MTX

12^a

206

68% (60%)

Etanercept as monotherapy

100

13^a

77% (69%)

4.26 (2.60; 7.00)

2.75 (1.70; 4.46)

Infliximab as monotherapy

0^a

56

45% (27%)

^aPatients not included in analysis. The hazard ratios were adjusted for differences in age, gender, 28-joint disease activity score (DAS28), health assessment questionnaire (HAQ) score, disease duration, previous disease-modifying antirheumatic drugs, and C-reactive protein (CRP) level. Data presented in the last column use HAQ score, DAS28, and CRP level as time-dependent covariates. For details, see Results. CI, confidence interval; MTX, methotrexate.

Kristensen et al. Arthritis Research & Therapy 2006 8:R174   doi:10.1186/ar2084